The proposed merger of Swiss pharmaceutical companies Sandoz and Ciba, announced last week, brings together two companies with extensive portfolios of biotechnology partnerships. These include multiple programs in gene and cell therapy, organ transplant, combinatorial chemistry, genomics and drug discovery.

The combined company, to be named Novartis, also will have gene mapping and sequencing collaborations with research institutions including